Literature DB >> 26549450

An Antifungal Combination Matrix Identifies a Rich Pool of Adjuvant Molecules that Enhance Drug Activity against Diverse Fungal Pathogens.

Nicole Robbins1, Michaela Spitzer1, Tennison Yu1, Robert P Cerone2, Anna K Averette3, Yong-Sun Bahn4, Joseph Heitman3, Donald C Sheppard5, Mike Tyers6, Gerard D Wright7.   

Abstract

There is an urgent need to identify new treatments for fungal infections. By combining sub-lethal concentrations of the known antifungals fluconazole, caspofungin, amphotericin B, terbinafine, benomyl, and cyprodinil with ∼3,600 compounds in diverse fungal species, we generated a deep reservoir of chemical-chemical interactions termed the Antifungal Combinations Matrix (ACM). Follow-up susceptibility testing against a fluconazole-resistant isolate of C. albicans unveiled ACM combinations capable of potentiating fluconazole in this clinical strain. We used chemical genetics to elucidate the mode of action of the antimycobacterial drug clofazimine, a compound with unreported antifungal activity that synergized with several antifungals. Clofazimine induces a cell membrane stress for which the Pkc1 signaling pathway is required for tolerance. Additional tests against additional fungal pathogens, including Aspergillus fumigatus, highlighted that clofazimine exhibits efficacy as a combination agent against multiple fungi. Thus, the ACM is a rich reservoir of chemical combinations with therapeutic potential against diverse fungal pathogens.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26549450      PMCID: PMC4654976          DOI: 10.1016/j.celrep.2015.10.018

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  36 in total

1.  Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans.

Authors:  Patrick Marichal; Luc Koymans; Staf Willemsens; Danny Bellens; Peter Verhasselt; Walter Luyten; Marcel Borgers; Frans C S Ramaekers; Frank C Odds; Hugo Vanden Bossche
Journal:  Microbiology       Date:  1999-10       Impact factor: 2.777

2.  Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011.

Authors:  Angela Ahlquist Cleveland; Monica M Farley; Lee H Harrison; Betsy Stein; Rosemary Hollick; Shawn R Lockhart; Shelley S Magill; Gordana Derado; Benjamin J Park; Tom M Chiller
Journal:  Clin Infect Dis       Date:  2012-08-14       Impact factor: 9.079

Review 3.  Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs.

Authors:  Jill R Blankenship; William J Steinbach; John R Perfect; Joseph Heitman
Journal:  Curr Opin Investig Drugs       Date:  2003-02

4.  The direct cost and incidence of systemic fungal infections.

Authors:  Leslie S Wilson; Carolina M Reyes; Michelle Stolpman; Julie Speckman; Karoline Allen; Johnny Beney
Journal:  Value Health       Date:  2002 Jan-Feb       Impact factor: 5.725

5.  A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.

Authors:  Arielle Butts; Louis DiDone; Kristy Koselny; Bonnie K Baxter; Yeissa Chabrier-Rosello; Melanie Wellington; Damian J Krysan
Journal:  Eukaryot Cell       Date:  2012-12-14

6.  Systematic discovery of multicomponent therapeutics.

Authors:  Alexis A Borisy; Peter J Elliott; Nicole W Hurst; Margaret S Lee; Joseph Lehar; E Roydon Price; George Serbedzija; Grant R Zimmermann; Michael A Foley; Brent R Stockwell; Curtis T Keith
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-10       Impact factor: 11.205

Review 7.  Hidden killers: human fungal infections.

Authors:  Gordon D Brown; David W Denning; Neil A R Gow; Stuart M Levitz; Mihai G Netea; Theodore C White
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

8.  Hsp90 governs dispersion and drug resistance of fungal biofilms.

Authors:  Nicole Robbins; Priya Uppuluri; Jeniel Nett; Ranjith Rajendran; Gordon Ramage; Jose L Lopez-Ribot; David Andes; Leah E Cowen
Journal:  PLoS Pathog       Date:  2011-09-08       Impact factor: 6.823

9.  Nontoxic antimicrobials that evade drug resistance.

Authors:  Stephen A Davis; Benjamin M Vincent; Matthew M Endo; Luke Whitesell; Karen Marchillo; David R Andes; Susan Lindquist; Martin D Burke
Journal:  Nat Chem Biol       Date:  2015-06-01       Impact factor: 15.040

10.  Combination antifungal therapy for cryptococcal meningitis.

Authors:  David G Lalloo; Jeremy J Farrar; Jeremy N Day; Tran T H Chau; Marcel Wolbers; Pham P Mai; Nguyen T Dung; Nguyen H Mai; Nguyen H Phu; Ho D Nghia; Nguyen D Phong; Cao Q Thai; Le H Thai; Ly V Chuong; Dinh X Sinh; Van A Duong; Thu N Hoang; Pham T Diep; James I Campbell; Tran P M Sieu; Stephen G Baker; Nguyen V V Chau; Tran T Hien
Journal:  N Engl J Med       Date:  2013-04-04       Impact factor: 91.245

View more
  33 in total

1.  Potent Antifungal Synergy of Phthalazinone and Isoquinolones with Azoles Against Candida albicans.

Authors:  Aaron D Mood; Ilandari Dewage Udara Anulal Premachandra; Stanley Hiew; Fuqiang Wang; Kevin A Scott; Nathan J Oldenhuis; Haoping Liu; David L Van Vranken
Journal:  ACS Med Chem Lett       Date:  2017-01-11       Impact factor: 4.345

Review 2.  Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity.

Authors:  Gina Wall; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

3.  High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method.

Authors:  Morgan A Wambaugh; Jessica C S Brown
Journal:  J Vis Exp       Date:  2018-05-21       Impact factor: 1.355

4.  Overcoming Fungal Echinocandin Resistance through Inhibition of the Non-essential Stress Kinase Yck2.

Authors:  Tavia Caplan; Álvaro Lorente-Macías; Peter J Stogios; Elena Evdokimova; Sabrina Hyde; Melanie A Wellington; Sean Liston; Kali R Iyer; Emily Puumala; Tanvi Shekhar-Guturja; Nicole Robbins; Alexei Savchenko; Damian J Krysan; Luke Whitesell; William J Zuercher; Leah E Cowen
Journal:  Cell Chem Biol       Date:  2020-01-07       Impact factor: 8.116

Review 5.  Antifungal adjuvants: Preserving and extending the antifungal arsenal.

Authors:  Arielle Butts; Glen E Palmer; P David Rogers
Journal:  Virulence       Date:  2016-07-26       Impact factor: 5.882

Review 6.  Combinatorial strategies for combating invasive fungal infections.

Authors:  Michaela Spitzer; Nicole Robbins; Gerard D Wright
Journal:  Virulence       Date:  2016-06-07       Impact factor: 5.882

7.  Clofazimine Reduces the Survival of Salmonella enterica in Macrophages and Mice.

Authors:  Toni A Nagy; Amy L Crooks; Joaquin L J Quintana; Corrella S Detweiler
Journal:  ACS Infect Dis       Date:  2020-04-29       Impact factor: 5.084

8.  A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in Candida Species.

Authors:  Arielle Butts; Parker Reitler; Andrew T Nishimoto; Christian DeJarnette; Leanna R Estredge; Tracy L Peters; Michael P Veve; P David Rogers; Glen E Palmer
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

9.  Species-specific activity of antibacterial drug combinations.

Authors:  Ana Rita Brochado; Anja Telzerow; Jacob Bobonis; Manuel Banzhaf; André Mateus; Joel Selkrig; Emily Huth; Stefan Bassler; Jordi Zamarreño Beas; Matylda Zietek; Natalie Ng; Sunniva Foerster; Benjamin Ezraty; Béatrice Py; Frédéric Barras; Mikhail M Savitski; Peer Bork; Stephan Göttig; Athanasios Typas
Journal:  Nature       Date:  2018-07-04       Impact factor: 49.962

10.  Phosphate is the third nutrient monitored by TOR in Candida albicans and provides a target for fungal-specific indirect TOR inhibition.

Authors:  Ning-Ning Liu; Peter R Flanagan; Jumei Zeng; Niketa M Jani; Maria E Cardenas; Gary P Moran; Julia R Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.